The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Open accessAbstract
Objective: To provide an overview for practicing clinicians on the pharmacological basis of cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness, to propose hypotheses to explain these risks and to give tips for managing cardiometabolic risk during antipsychotic treatment. Method: A MEDLINE search using terms for atypical antipsychotics (including individual drug names), metabolic, cardiovascular, weight gain and insulin resistance, cross‐referenced with schizophrenia was performed on articles published between 1990 and May 2008. Results: Strong evidence exists for significant cardiometabolic risk differences among several antipsychotic agents. Histamine H1 and serotonin 5HT2C antagonism are associated with risk of weight gain, but receptor targets for dyslipidemia and insulin resistance have not yet been identified. Convincing data indicate that hypertriglyceridemia and insulin resistance may occur in the absence of weight gain with certain antipsychotics. Conclusion: Although lifestyle and genetics may contribute independent risks of cardiometabolic dysfunction in schizophrenia and other serious mental illness, antipsychotic treatment also represents an important contributor to risk of cardiometabolic dysfunction, particularly for certain drugs and for vulnerable patients. Mental health professionals must learn to recognize the clinical signposts indicating antipsychotic‐related cardiometabolic problems to forestall progression to type II diabetes, cardiovascular events and premature death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Prevalence of Overweight and Obesity in the United States
Crespo, C. J., & Ellen, S. (2003) · Obesity: Etiology Assessment Treatment and Prevention · doi:10.5040/9781718206601.ch-001 · Cited by 4,379
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors
Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F., & Julius, D. (1995) · Nature · doi:10.1038/374542a0 · Cited by 1,274
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714
Carey, D. G., Jenkins, A. B., Campbell, L. V., Freund, J., & Chisholm, D. J. (1996) · Diabetes · doi:10.2337/diab.45.5.633 · Cited by 659
Osborn, D. P. J., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.242 · Cited by 608
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
“People with SMI are more likely to be overweight, to smoke and to have diabetes, hypertension and dyslipidaemia [31,39,45,46,93,99,100,121].”
BackgroundThe dietary pattern of patients with schizophrenia: A systematic review
Dipasquale, S., Pariante, C. M., Dazzan, P., Aguglia, E., McGuire, P., & Mondelli, V. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.10.005 · Cited by 394
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Metadata
- Authors
- Stahl, S. M., Mignon, L., & Meyer, J. M.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2009-01-27
- Volume
- 119
- Issue
- 3
- Pages
- 171-179
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2014202818
- Cited by
- 259
- References
- 50
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Which comes first: atypical antipsychotic treatment or cardiometabolic risk? https://app.cochat.ai/papers/10.1111/j.1600-0447.2008.01334.x
- The paper
- Stahl, S. M., Mignon, L., & Meyer, J. M. (2009). Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2008.01334.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.